
About Tevapharm India Private Limited
Data last updated:
Tevapharm India Private Limited is a foreign private limited company based in Mumbai, Maharashtra, India, a subsidiary of Ratiopharm Gmbh. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 01 December 2000 and has been in existence for over 26 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U33111MH2000FTC326700. Its GSTIN is 27AABCR7561F1ZA (Maharashtra). The company holds 5 GST registrations, of which 4 are active.
The company has an authorised share capital of ₹700 Cr and a paid-up capital of ₹220.19 Cr. It was formerly known as Ratiopharm India Private Limited. It is led by directors including Nishank Bhargava and Pooja Singh.
Its last annual general meeting (AGM) was held on 01 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹459.24 Cr, a decline of 9% compared to the previous year. For the same year it recorded a net profit of ₹66.56 Cr (net margin 14.5%) and EBITDA of ₹103.72 Cr (EBITDA margin 22.6%). Revenue has grown at a compounded annual rate (CAGR) of 24% over three years and 6% over five years.
The company has about 954 employees on its provident fund (EPFO) records.
Court records list 4 cases involving the company, including 4 filed against it. The company has 10 deals on record (5 funding rounds, 4 secondary share transfers, 1 acquisition), with disclosed funding of ₹399.66 Cr; the latest was in September 2023. The company has 13 MSME Form 1 returns on record between 2019 and 2024, listing 415 overdue payments to 86 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website tevapharm.com.
Company details
CIN history
Tevapharm India has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U33111MH2000FTC326700, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U33111MH2000FTC326700 | Current |
| U33111DL2000FTC268478 | Previous |
| U33111MH2000FTC129835 | Previous |
Contact details
Tevapharm India Private Limited's registered office is in Mumbai, Maharashtra. Its website is tevapharm.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address8th Floor Tower C Times Square Andheri Kurla Road Gamdevi Marol Andh, Eri East, Mumbai, Maharashtra, India – 400059
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Tevapharm India Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Tevapharm India is professional, scientific and technical. In detail, this covers other professional, scientific and technical activities.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M9 | Other professional, scientific and technical activities |
To see the full business activity and turnover split of Tevapharm India Private Limited, buy the company report.
Financials of Tevapharm India Private Limited
FY 2025 filings availableTevapharm India Private Limited reported revenue of ₹459.24 Cr (down 9% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 9% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 6%. EBITDA rose 9% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹103.72 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹66.56 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 22.6% | ||||
| Net Profit Margin | 14.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Tevapharm India Private Limited, buy the company report.
Board of directors of Tevapharm India Private Limited
Tevapharm India has 4 current directors and 30 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Nishank Bhargava | Director | 24 Feb 2022 | 4 Years 8 Months | Current |
| Pooja Singh Also directs: Teva Global Business Services Private Limited | Director | 03 Jun 2025 | 1 Years 5 Months | Current |
| Vinod Narayan Shetty | Director | 24 Aug 2021 | 5 Years 2 Months | Current |
| Gubbi Channappa Roopa | Director | 27 Jun 2024 | 2 Years 4 Months | Current |
Auditor
Tevapharm India Private Limited is audited by SRBC & CO LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SRBC & CO LLP | FY 2023 | 324982E/E300003 |
Shareholding
The shareholding of Tevapharm India Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Tevapharm India Private Limited, buy the company report.
Deals & funding
Tevapharm India Private Limited has 10 deals on record (5 funding rounds, 4 secondary share transfers, 1 acquisition), with disclosed funding of ₹399.66 Cr; the latest was in September 2023.
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2023 | Secondary share transfer | Undisclosed | Seller: Teva Pharmaceutical Investments Singapore Pte Limited |
| Oct 2022 | Acquisition | Undisclosed | Buyer: Marksans Pharma Limited Seller: Tevapharm India Private Limited |
| Apr 2022 | Secondary share transfer | Undisclosed | Seller: Teva Pharmaceutical Investments Singapore Pte Limited |
| Jul 2020 | Secondary share transfer | Undisclosed | Seller: Teva Pharmaceutical Investments Singapore Pte Limited |
| Mar 2019 | Secondary share transfer | Undisclosed | Seller: Teva Pharmaceutical Investments Singapore Pte Limited |
To see the full deal history of Tevapharm India Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Tevapharm India Private Limited has 4 court cases on record: 4 filed against it. All cases are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 3 | 3 | 0 |
| District courts | 1 | 1 | 0 |
Cases on record (4 of 4)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Ahmedabad, Gujarat | Criminal complaint | Filed against the company by Yes Bank Ltd - Chinmay H. Acharya | Disposed |
| High Court of Gujarat | Special civil application | Filed against the company by M/S Gillette Diversified Operations Pvt. Ltd. | Disposed |
| High Court of Delhi | Court case (CS(OS)) | Filed against the company by an individual | Disposed |
| High Court of Delhi | Tax appeal | Filed against the company by PR. Commissioner of Income Tax- 9 | Disposed |
To see the full case history of Tevapharm India Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Tevapharm India Private Limited has 13 MSME Form 1 returns on record between 2019 and 2024, listing 415 overdue payments to 86 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 86)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Perks Links and Services Private Limited | |||
| an individual supplier | |||
| an individual supplier | |||
| Zalani Stationery Mart |
To see the full MSME payment records of Tevapharm India Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Tevapharm India Private Limited has a workforce of 954 employees on its EPFO records as of May 2026, across 2 active EPFO establishments.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 954 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Tevapharm India Private Limited, buy the company report.
GST
Tevapharm India has 5 GST registrations: 4 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AABCR7561F1ZA | Maharashtra | Active | 01 Jul 2017 |
| 27AABCR7561F2Z9 | Maharashtra | Active | 11 Mar 2025 |
| 30AABCR7561F1ZN | Goa | Active | 01 Jul 2017 |
| 29AABCR7561F1Z6 | Karnataka | Active | 25 Nov 2019 |
To see the full GST registrations and return filing status of Tevapharm India Private Limited, buy the company report.
Recent activity
Tevapharm India Private Limited has 32 board changes on record since 2008: 4 appointments and 28 cessations. The latest: Pooja Singh ceased to be Additional Director on 31 Aug 2025.
23 earlier events are in the company report.
News
Frequently asked questions
Tevapharm India is an active foreign private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 01 December 2000 (26+ years old) and is registered under CIN U33111MH2000FTC326700.
Tevapharm India has 4 current directors:
- Nishank Bhargava - Director
- Pooja Singh - Director
- Vinod Narayan Shetty - Director
- Gubbi Channappa Roopa - Director
The latest financial statements of Tevapharm India on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 01 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Tevapharm India is 27AABCR7561F1ZA, registered in Maharashtra. The company has 5 GST registrations in all, of which 4 are active and 1 is cancelled or inactive. Other active GSTINs include 27AABCR7561F2Z9 (Maharashtra), 30AABCR7561F1ZN (Goa), 29AABCR7561F1Z6 (Karnataka).
The CIN (Corporate Identification Number) of Tevapharm India is U33111MH2000FTC326700. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Tevapharm India has 4 court cases on record: 4 filed against it. Most are in the high courts.
Tevapharm India was incorporated on 01 December 2000, making it 26+ years old. It is registered with the Registrar of Companies, Mumbai.
Tevapharm India has 10 deals on record (5 funding rounds, 4 secondary share transfers, 1 acquisition), with disclosed funding of ₹399.66 Cr; the latest was in September 2023.
Pooja Singh ceased to be Additional Director on 31 Aug 2025. Pooja Singh was appointed as Director on 03 Jun 2025. Gubbi Channappa Roopa ceased to be Additional Director on 01 Sep 2024. Tevapharm India has 32 board changes on record in total.
Tevapharm India has 13 MSME Form 1 returns on record between 2019 and 2024, listing 415 overdue payments to 86 micro and small suppliers. The latest return was filed on 29 Apr 2024.
Tevapharm India can be reached through the website tevapharm.com. Its registered office is in Mumbai, Maharashtra, India.

